Helen Reynolds

Years Active: 2019-2021
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, Izabela Eberhart, Christie Woods, Sean Ewings, Colin Hale, Rajith K R Rajoli, Laura Else, Sujan Dilly-Penchala, Alieu Amara, David G Lalloo, Michael Jacobs, Henry Pertinez, Parys Hatchard, Robert Waugh, Megan Lawrence, Lucy Johnson, Keira Fines, Helen Reynolds, Timothy Rowland, Rebecca Crook, Emmanuel Okenyi, Kelly Byrne, Pavel Mozgunov, Thomas Jaki, Saye H Khoo, Andrew Owen, Gareth Griffiths, Thomas E Fletcher, null null
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. Clinical pharmacology and therapeutics (2021)
Catriona Waitt, Catherine Orrell, Stephen Walimbwa, Yashna Singh, Kenneth Kintu, Bryony Simmons, Julian P Kaboggoza, Mary Sihlangu, Julie-Anne Coombs, Thoko Malaba, Josaphat K Byamugisha, Alieu Amara, Joshua Gini, Laura Else, Christie Heiburg, Eva Maria Hodel, Helen Reynolds, Ushma C Mehta, Pauline Byakika-Kibwika, Andrew Hill, Landon Myer, Mohammed Lamorde, Saye H Khoo
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS medicine 16 (9) (2019)

Helen Reynolds.css-eqlu8i{font-size:small;padding-left:4px;}